Type 2 Diabetes | Pharmacor | G7 | 2014
Last Updated 12 September 2014
The type 2 diabetes therapy market will rapidly expand over our 2013-2023 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. Among the drug classes expected to undergo the most rapid growth is the sodium glucose cotransporter (SGLT)-2 inhibitors, led by AstraZeneca’s dapagliflozin (Forxiga/Farxiga) and Johnson & Johnson/Mitsubishi Tanabe Pharma’s canagliflozin (Invokana). However, these and other emerging therapies will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment. Nevertheless, as the patient population expands and significant needs remain, commercial opportunity will continue to grow.
